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IL-6 is a central mediator of the immediate induction of hepatic acute phase proteins
(APP) in the liver during infection and after injury, but increased IL-6 activity has
been associated with multiple pathological conditions. In hepatocytes, IL-6 activates
JAK1-STAT3 signaling that induces the negative feedback regulator SOCS3 and
expression of APPs. While different inhibitors of IL-6-induced JAK1-STAT3-signaling
have been developed, understanding their precise impact on signaling dynamics
requires a systems biology approach. Here we present a mathematical model
of IL-6-induced JAK1-STAT3 signaling that quantitatively links physiological IL-6
concentrations to the dynamics of IL-6-induced signal transduction and expression
of target genes in hepatocytes. The mathematical model consists of coupled
ordinary differential equations (ODE) and the model parameters were estimated
by a maximum likelihood approach, whereas identifiability of the dynamic model
parameters was ensured by the Profile Likelihood. Using model simulations coupled
with experimental validation we could optimize the long-term impact of the JAK-inhibitor
Ruxolitinib, a therapeutic compound that is quickly metabolized. Model-predicted
doses and timing of treatments helps to improve the reduction of inflammatory
APP gene expression in primary mouse hepatocytes close to levels observed
during regenerative conditions. The concept of improved efficacy of the inhibitor
through multiple treatments at optimized time intervals was confirmed in primary
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human hepatocytes. Thus, combining quantitative data generation with mathematical
modeling suggests that repetitive treatment with Ruxolitinib is required to effectively
target excessive inflammatory responses without exceeding doses recommended by
the clinical guidelines.
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INTRODUCTION
Increased activity of interleukin (IL)-6 has been associated with
chronic inflammatory diseases including rheumatoid arthritis
(Hirano et al., 1988), multiple sclerosis (Frei et al., 1991;
Navikas et al., 1996), and Crohn’s disease (Ito, 2003). High
IL-6 levels are also frequently found and correlate with poor
outcome in patients with sepsis, an acute systemic inflammatory
response (Waage et al., 1989; Calandra et al., 1991; Damas et al.,
1992; Norrby-Teglund et al., 1995). Accordingly, abrogation of
glycoprotein 130 (gp130)-dependent signaling in hepatocytes
was shown to prolong survival and to reduce liver damage
in an in vivo sepsis model (Klein et al., 2007). Persistent
inflammation can initiate or promote (Grivennikov and Karin,
2011) malignant progression and a pro-tumorigenic role of IL-6,
which is elevated in many types of cancer, has been suggested
(Heikkila et al., 2008). Thus, increased IL-6 levels can have
detrimental effects. On the other hand, a certain amount of
IL-6 is required for efficient immune defense (Kopf et al., 1994)
and liver regeneration (Cressman et al., 1996; Sakamoto et al.,
1999; Zimmers et al., 2003). Central target cells of IL-6 are
hepatocytes, where IL-6 regulates the production of acute phase
proteins (APPs) by first activating the IL-6 receptor complex
with the signal-transducing subunit gp130. Signals are further
transduced via janus kinase 1 (JAK1) and signal transducer
and activator of transcription 3 (STAT3; Bode and Heinrich,
2001).
However, other cytokines such as Oncostatin-M (OSM), IL-
11, IL-10, and IL-22, also induce STAT3 phosphorylation (see
Nakamura et al., 2004; Sabat et al., 2010; Nishina et al., 2012;
Rao et al., 2014) and therefore could contribute to the complex
regenerative and inflammatory signaling in the liver. OSM is
also able to induce IL-6 expression and therefore additionally
feeds into JAK1/STAT3 signaling. However, OSM is primarily
involved in developmental processes (Nakamura et al., 2004) and
presumably only contributes to a lesser extent to the immediate
activation of the acute phase response upon liver damage. IL-
11 was shown to be mainly involved in hepatocellular responses
upon oxidative stress and hepatotoxic drugs (Nishina et al.,
2012). The anti-inflammatory cytokine IL-10 is an essential
factor controlling inflammation (Murray, 2006). After partial
hepatectomy Yin et al. observed after 1 h an increase in Il10
mRNA expression, but the concentration of IL-10 protein was not
examined (Yin et al., 2011). Distinct from IL-6, IL-10 apparently
does not induce the expression of suppressor of cytokine
signaling 3 (SOCS3), (Ichikawa et al., 2002) and in mice lacking a
functional Socs3 gene in macrophages or neutrophils no obvious
alteration in IL-10 signal transduction is observed (Yasukawa
et al., 2003). For IL-22 Rao et al. observed in hepatectomizedmice
in comparison to sham operated mice an increase of Il22 mRNA
after 1 h and a further increase after 3 h, whereas Il6 mRNA was
already maximally induced after 1 h (Rao et al., 2014). On the
other hand Ren et al. did not detect a statistically significant
increase of Il22 mRNA in mice in response to hepatectomy, but
rather reported a statistically significant increase of IL-22 protein
in the serum starting at 6 h post hepatectomy with a peak at
12 h (Ren et al., 2010). Further, in response to LPS injection a
very low level of induction of Il22 mRNA was observed in the
liver with a peak at 4 h post injection, whereas a much stronger
activation of Il22 mRNA with comparable kinetics was observed
in the spleen (Wegenka et al., 2007). Likewise, Dumoutier et al.
reported that IL-22 is primarily produced by innate spleen cells
in mice. These studies showed a peak of Il22 mRNA in the
serum after 2–3 h post LPS injection and elevated serum levels
of IL-22 at 4 h post treatment (Dumoutier et al., 2011). Analysis
of IL-22 knockout mice revealed that in the absence of IL-22
hepatocellular proliferation at 48 h post hepatectomy is reduced
(Kudira et al., 2016). Further, 6 h post LPS injection a very
heterogeneous decrease in STAT3 phosphorylation is observed
in IL-22 knockout mice compared to wild type mice (Wallace
and Subramaniam, 2015) and the authors concluded that the IL-
22 knockout mice display appropriate inflammatory responses
to LPS in the liver. Together these studies suggest that IL-
22 is a mediator of the cross-talk between immune cells and
hepatocytes and contributes to efficient liver regeneration but
potentially distinct from IL-6 primarily contributes to long-term
recovery.
IL-6/STAT3-dependent target genes encode the APPs
fibrinogen-γ (Fgg), serum amyloid P (Apcs), haptoglobin
(Hp), hemopexin (Hpx; Alonzi et al., 2001), hepcidin (Hamp;
Wrighting and Andrews, 2006; Pietrangelo et al., 2007), as
well as Socs3, the negative feedback regulator of IL-6 signaling
(Starr et al., 1997; Croker et al., 2003). Although, APPs fulfill
beneficial roles in host defense and tissue repair (Bode et al.,
2012), several adverse effects have been reported for different
APPs. Hepcidin, for instance, a crucial regulator of iron
homeostasis (Sakamori et al., 2010; Ganz and Nemeth, 2012),
contributes to the development of anemia under inflammatory
conditions (Weinstein et al., 2002; Kemna et al., 2005).
Elevated expression of fibrinogen was related to formation
and progression of atherosclerotic plaques (Levenson et al.,
1995) and serum amyloid P, the major APP in mice, was
suggested to contribute to the persistence of amyloid deposits
(Tennent et al., 1995). Dysregulated APP production may thus
foster pathologic changes during uncontrolled inflammatory
responses.
Triggered by its involvement in several pathologies,
therapeutic targeting of IL-6 signaling is a focus of ongoing
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basic and clinical investigations. The JAK1/2 inhibitor
Ruxolitinib/INCB018424 (Jakavi/Jakafi, Incyte Pharmaceuticals,
Novartis; Lin et al., 2009; Quintas-Cardama et al., 2010) has
been internationally approved for the therapy of myelofibrosis
(Mesa et al., 2012; Verstovsek et al., 2012) and polycythemia
vera (Vannucchi et al., 2015), which are frequently caused
by the V617F gain-of-function mutation within JAK2
(Kralovics et al., 2005). According to the guidelines, the
recommendation for Jakavi is a repetitive, constant dose of
10 mg twice daily (q12h) for polycythemia vera or 20 mg
twice daily (q12h) for myelofibrosis (Rote, 2016). Ruxolitinib
affects the hematological status of patients and therefore
the platelet count should be assessed before the start of a
therapy. Since low neutrophil counts have been observed in
66% of healthy volunteers treated with 100 mg Ruxolitinib
daily (q24h; Shi et al., 2011), it is of great importance not
to exceed the recommended daily doses. Ruxolitinib is also
tested for the treatment of other malignancies as well as
chronic inflammatory diseases such as rheumatoid arthritis
(Williams et al., 2008; Quintas-Cardama et al., 2011).
The STAT3 inhibitor Stattic, which is not approved for
clinical applications, targets the STAT3 SH2 domain, thus
blocking receptor association and dimerization. Stattic
treatment inhibited IL-6-induced STAT3 phosphorylation
and nuclear translocation in hepatocytes (Schust et al.,
2006). Moreover, increased apoptosis was observed in
STAT3-dependent cancer cell lines upon Stattic treatment
(Schust et al., 2006). Although the molecular mechanisms of
Ruxolitinib and Stattic are well-established, their impact on
the dynamics of signal transduction, expression of target genes,
and cellular response is, due to the non-linear reactions, not
intuitive.
Mathematical models based on ordinary differential equations
(ODEs) are well-suited to study the dynamics of signal
transduction and have enabled the identification of therapeutic
targets within signaling networks (Schoeberl et al., 2009; Raia
et al., 2011). ODEs describe concentration changes of species over
time. The law of mass-action kinetics defines a reaction rate to
be proportional to the concentrations of reacting biomolecules
thus facilitating the translation of a pathway map into a set
of ODEs. In the model, species concentrations are the state
variables, while rate constants, initial conditions, or other
proportionality factors are termed parameters. Although, some
parameter values such as initial protein concentrations may
be accessible by measurements, most parameter values remain
unknown and have to be estimated based on experimental
data (Aldridge et al., 2006; Chen et al., 2010). This process
is called model calibration and requires highly quantitative
and reproducible experimental data, as well as a sufficient
number of data points and measured species (Bachmann et al.,
2012).
Formulating biological hypotheses in terms of mathematical
models allows to quantitatively test such hypotheses by
challenging model predictions with additional experimental
data. For example Swameye et al. established a dynamic
pathway model for the JAK2-STAT5 signaling pathway and
tested conflicting hypothesis on signal transduction from
the cell surface receptor to the nucleus (Swameye et al.,
2003). The mathematical model revealed that STAT5 acts
as a remote sensor for receptor activation and that repeated
nucleocytoplasmic cycling of STAT5 is required for effective
target gene activation in the nucleus. Furthermore, by a
mathematical modeling approach Sasagawa et al. showed that
the transient activation of ERK depends on rapid increases
in the amount of epidermal growth factor and nerve growth
factor (NGF), while sustained ERK activation depends on
the final NGF concentration (Sasagawa et al., 2005). Nelson
et al. revealed that oscillations observed in TNFalpha induced
activation of NF-kB control the dynamics of gene expression.
The mathematical modeling approach revealed that two
molecular species were strongly coupled to the oscillation
dynamics (Nelson et al., 2004). By iteratively combining
mathematical modeling with model-guided experiments,
these and other studies (Alon et al., 1999; Sick et al., 2006;
Borisov et al., 2009; Becker et al., 2010; Bachmann et al.,
2011) demonstrated that it is possible to capture biological
behavior, reject hypotheses which fail to describe data and
make non-trivial predictions for validation experiments.
Moreover, uncertainty analysis can give insight into how
well a model is constrained and what kind of predictive
power one can expect when predicting similar experiments
(Kreutz et al., 2012; Vanlier et al., 2013). Additionally,
validation experiments guided by well-constrained predictions
can be performed to improve the confidence in the model
(Steiert et al., 2012).
Although several ODE-based mathematical models of IL-
6 signaling have been reported to date (Singh et al., 2006;
Moya et al., 2011; Dittrich et al., 2012), only with a recently
described mathematical model (Xu et al., 2015) potential effects
of targeting selected pathway components on APP expression
were tested in silico. These studies predicted that IL-6 signaling
could be best targeted at the receptor level, and that reduced
inhibitor dose may be achievable by applying possible inhibitor
combinations (Xu et al., 2015). However, the model-based
predictions reported by Xu et al. were not experimentally
validated, thus limiting applicability to targeting IL-6 signaling
in human disease.
Here we present an ODE model of IL-6-induced JAK1-STAT3
signaling in primary mouse hepatocytes. Based on extensive
experimental data, the mathematical model describes pathway
activation and key target gene induction during regenerative
and inflammatory conditions, as well as the impact of the
pathway inhibitors Ruxolitinib and Stattic. We combined model
predictions with experimental validation to optimize the long-
term Ruxolitinib-mediated reduction of APP gene expression,
while maintaining gene expression levels that are present during
regenerative conditions without employing excessive inhibitor
concentrations. The presented approach represents a starting
point for systematic clinical intervention in inflammatory or
malignant diseases.
Frontiers in Physiology | www.frontiersin.org 3 October 2017 | Volume 8 | Article 775
Sobotta et al. Targeting IL-6 Signaling in the Liver
RESULTS
Physiological IL-6 Concentrations during
Liver Regeneration and Inflammation
A broad range of circulating IL-6 concentrations has been
reported during liver regeneration (Slotwinski et al., 2002;
Nechemia-Arbely et al., 2011; Yin et al., 2011) and inflammation
(Waage et al., 1989; Damas et al., 1992; Piao et al., 2013),
but a direct comparison of regenerative and inflammatory
conditions has not been performed yet. To provide a basis
for our ex vivo experiments and to enable model predictions
of physiological relevance, we determined physiological IL-6
concentrations in mice following partial hepatectomy (PHx;
Mitchell and Willenbring, 2008) and lipopolysaccharide (LPS)
injection (Fattori et al., 1994; Copeland et al., 2005), which trigger
liver regeneration and acute inflammation, respectively. Serum
IL-6 levels were measured using a bead-based immunoassay.
We observed rapid but transient induction of serum IL-6 in
response to PHx and LPS treatment (Figure 1A). Peak IL-
6 levels were detected 2 h post PHx with 1.4 ng/mL (±0.3
ng/mL SD; n = 3). Similarly, IL-6 amounts in response to
LPS injection peaked at 2 h, but reached considerably higher
concentrations of 201.8 ng/mL (±77.8 ng/mL SD; n = 5).
Following the peak, IL-6 levels dropped quickly and returned
to baseline levels at 8–24 h. For comparison, sham surgery
and NaCl injection as control treatments for PHx and LPS,
respectively, caused serum IL-6 levels to increase only slightly.
Less than 0.4 ng/mL IL-6 after sham surgery and <0.1 ng/mL
IL-6 after NaCl injection were measured. The background IL-
6 concentration in untreated mice was <10 pg/mL, which
corresponds to previously reported values (Huang et al.,
2003). To conclude, IL-6 levels in response to PHx and LPS
treatment increased in a fast but transient manner. Similar
dynamics were observed for PHx and LPS treatment. However,
LPS caused 100-fold higher peak IL-6 levels, compared to
PHx.
In addition to serum IL-6 levels, we developed a strategy to
determine the IL-6 concentrations present in the hepatocytes’
microenvironment. We analyzed STAT3 activation (Tyr-705
phosphorylation) as read-out in livers from PHx and LPS-treated
mice. Phospho-STAT3 levels were measured using multiplexed
bead-based arrays (Figure 1B), revealing rapid and transient
induction of STAT3 activation after PHx and LPS treatment.
Peak levels were reached at 2 h following PHx and even earlier,
after 1 h following LPS injection. Thus, the conversion of IL-
6 signal to STAT3 activation is very efficient. The amplitude of
STAT3 activation after LPS treatment was more than twice as
high as in the case of PHx. After peaking, the phospho-STAT3
signal decreased likewise in PHx and LPS treated livers, and
returned to levels close to baseline at 24 h. STAT3 activation was
also detectable in animals treated with sham surgery, which has
been reported previously (Cressman et al., 1996; Heim et al.,
1997), and which is likely due to stress caused by the surgical
procedure.
To compare the contribution of IL-6 and of the other
STAT3 activating cytokines IL-22, OSM, or IL-11, on STAT3
phosphorylation in the liver, we performed additional
time-resolved qRT-PCR measurements of liver lysates from
LPS or PHx treated mice. In comparison to the induction of
IL-6 protein expression (Figure 1A) and Il6 gene expression
(Appendix Figure S14) no major induction of OSM, IL-22, or
IL-11 was elicited by partial hepatectomy or by LPS (Appendix
Figure S14).
In parallel, phospho-STAT3 levels were determined in primary
mouse hepatocytes stimulated with 0.1–500 ng/mL recombinant
human IL-6 (hIL-6) for 20min to capture the maximal phospho-
STAT3 signal (Figure 1C). When the work of the presented study
was initiated, recombinant murine IL-6 was not yet commercially
available. Therefore, human IL-6, produced as described in
Vandam et al. (1993), was utilized and was kept for the entire
study to ensure consistency.
Samples from mouse livers (Figure 1B) and from primary
mouse hepatocytes (Figure 1C) were analyzed simultaneously
in a 96-well plate format using equal lysis conditions for direct
comparability of the measured phospho-STAT3 signal. Dose-
dependent STAT3 activation in primary mouse hepatocytes
followed a sigmoidal behavior in response to IL-6. It was
detectable from 2.5 ng/mL hIL-6 on, then steeply increased
and quickly reached saturation at 25–50 ng/mL (Figure 1C).
Approximation of the IL-6/phospho-STAT3 dose-response curve
from primary mouse hepatocytes by a 4-parameter Hill
regression function enabled to correlate phospho-STAT3 signal
intensities in livers from PHx or LPS-treated mice to IL-6
concentrations that elicited the observed STAT3 response. The
peak phospho-STAT3 signal (average ± SEM of 2 and 3 h
time points) after PHx approximately corresponded to an IL-
6 concentration equivalent to 6.8–7.9 ng/mL hIL-6. In the case
of LPS, the peak phospho-STAT3 signal (average ± SEM of 1
and 2 h time points) approximately corresponded to a signal
obtained with 28.1–500 ng/mL hIL-6. The STAT3 signal detected
after NaCl injection was out of range of our reference curve and
corresponded to<0.1 ng/mL hIL-6 (Figure 1C).
To convert the responses elicited by hIL-6 to the
concentrations relevant in the mouse, we performed dose
response experiments comparing the potency of increasing
doses of human and murine IL-6 in stimulating STAT3
phosphorylation in primary mouse hepatocytes. As shown in
Figure 1D, this revealed that murine IL-6 is more potent to elicit
STAT3 phosphorylation in murine hepatocytes compared to
hIL-6 with an overall shift of the dose-response curve to lower
IL-6 concentrations. Collectively, STAT3 was activated rapidly,
efficiently and transiently in mouse livers after PHx and LPS
treatment. In line with IL-6 serum concentrations (Figure 1A),
peak phospho-STAT3 signals corresponded to human IL-6
concentration ranges for PHx (6.8–7.9 ng/mL; average: 7.4
ng/mL) and LPS (28.1–500 ng/mL; average: 264.1 ng/mL). This
corresponds to a mouse IL-6 concentration of 1.8 and 50 ng/mL,
respectively (Figure 1D).
Time-Resolved Characterization of Key
IL-6 Target Genes
To investigate the APP gene signature induced by hIL-6 in
primary mouse hepatocytes, and to establish the time-dependent
Frontiers in Physiology | www.frontiersin.org 4 October 2017 | Volume 8 | Article 775
Sobotta et al. Targeting IL-6 Signaling in the Liver
FIGURE 1 | Physiological IL-6 concentrations during liver regeneration and inflammation. Mice were subjected to control (Sham) surgery or partial hepatectomy (PHx),
and control (NaCl) or lipopolysaccharide (LPS, 1 µg/g body weight) treatment. Serum and livers were collected at indicated time points. (A) Absolute serum IL-6 levels
were measured by a bead-based immunoassay. Filled circles represent data from individual mice, solid lines connect average values of biological replicates. Sham,
PHx, and LPS-treatment: n = 3–6 per time point; NaCl: n = 1 per time point. (B) STAT3 phosphorylation at Tyr-705 was quantified by multiplexed bead-based arrays
in lysates of frozen mouse liver samples. Per time point or IL-6 dose, 3–6 biological replicates were measured and scaled by normalizing to their average signal. Filled
circles represent average ±standard error of the mean (SEM) of biological replicates; solid lines are shown for visual guidance in the mouse liver data set. (C) Primary
mouse hepatocytes were stimulated with 0.1–500 ng/mL of recombinant human IL-6, and lysed after 20min. The 4-parameter Hill regression function (C) was
generated using SigmaPlot software, and served to convert phospho-STAT3 signals to IL-6 concentrations. Dashed lines represent average phospho-STAT3 signals
of the 1 and 2 h time points (NaCl, LPS), or 2 and 3 h time points (PHx), and corresponding derived IL-6 concentrations. Shaded areas represent standard error of the
mean. (D) Primary mouse hepatocytes were stimulated with mouse IL-6 or human IL-6 to derive the doses of human IL-6 mimicking regenerative and inflammatory
conditions, indicating that 1.8 ng of mouse IL-6 is equally potent to 7.5 ng of human IL-6 on mouse hepatocytes. FI, fluorescence intensity; a.u., arbitrary units.
regulation of respective genes, we performed microarray analysis
of primary mouse hepatocytes stimulated with hIL-6 (40 ng/mL)
for up to 32 h. Global analysis of the genome-wide transcriptome
profiling was performed using principal component (PC) analysis
(PCA). In the two most relevant PCs the samples were
separated by time and by condition (control vs. hIL-6) and
biological duplicates were clustered (Figure 2A) indicating high
reproducibility. The individual contributions of genes to the
two PCs are shown in the respective rotation space for PC1/2
(Figure 2B). We found well-established IL-6 targets, such as
Socs3 and the APP genes Apcs, Fgg, and Hamp to be major
contributors to both, stimulus-specific and time-dependent,
regulation (Figure 2B).
Differential gene expression analysis of the microarray
data set was performed using a linear regression model
with gene-wise Bayesian variance estimation (Ritchie et al.,
2015). We classified the IL-6-regulated genes as early (0.5–
2 h), intermediate (4–16 h), and late (24–32 h) response genes
to establish optimized time frames for the measurements
(Figure 2C). In total 1,728 genes were significantly regulated
upon hIL-6 stimulation (Appendix Figure S1A), while 723,
779, and 694 genes were IL-6-regulated at early, intermediate,
and late time points, respectively. Intermediate and late IL-6-
response genes showed more than 40% overlap. Enrichment
analysis of respective gene lists showed that the late IL-6
response was enriched for genes relevant in the acute phase
response (Appendix Figure S1B). Significantly regulated genes
included Socs3, which was induced at early, intermediate, and
late time points. Another early-induced gene was Cxcl10. We
found the APP genes Fgg, Hamp, and Il33 to be induced
at intermediate and late time points, whereas compared with
control Apcs was increased only at late time points. Interestingly,
the gene encoding the C reactive protein (CRP), displayed
a similar expression pattern as Apcs. Hierarchical clustering
of significantly regulated genes and further APP genes of
interest (Heinrich et al., 1990) revealed that especially late APP
Frontiers in Physiology | www.frontiersin.org 5 October 2017 | Volume 8 | Article 775
Sobotta et al. Targeting IL-6 Signaling in the Liver
FIGURE 2 | Genome-wide analysis of IL-6-induced transcriptional responses. (A) Primary mouse hepatocytes were stimulated with 40 ng/mL hIL-6 or left untreated
(Control), and RNA was isolated at indicated time points. Transcriptome profiling was performed using GeneChip Mouse Genome 430 2.0 Arrays (Affymetrix). Samples
were projected onto the first two principal components (PC) of the data set, and values in PC1/2 are plotted. Arrows connect subsequent time points for Control and
IL-6 condition, and are shown for visual guidance. (B) Contributions of individual genes to the respective PCs are shown. Genes of interest are labeled and highlighted
in blue (APP), or dark red (Socs3). (C) Hierarchical clustering of expression patterns of APP genes of interest. Expression values are centered to mean expression of t
= 0 Control samples. Sidebar color-codes whether genes were significantly regulated at early, intermediate, or late time points. APPs that are most relevant in the
murine context are highlighted in yellow. CRP, an important APP in the human context, is highlighted in orange.
genes clustered and were mostly induced upon hIL-6 treatment
(Figure 2C).
Taken together, we present a comprehensive list of IL-6 target
genes that are expressed in response to hIL-6 stimulation in
primary mouse hepatocytes. Of these we obtained detailed time-
resolved expression profiles of previously known (Apcs, Fgg,
Hamp, Hp, Hpx, Socs3) and less well-established (Cxcl10, Il33)
IL-6 target genes. These selected genes served as read-out for
the IL-6-induced hepatic acute phase response in the following
experiments, and the recorded temporal dynamics enabled the
choice of optimal time points for dose-dependent analysis.
Dynamic Mathematical Model of IL-6
Signaling Capturing Inhibitor Effects
To link the observed physiological IL-6 concentrations to
activation of signal transduction and induction of target genes
and to quantitatively predict the impact of the pathway inhibitors
Ruxolitinib and Stattic, we generated amathematical model of IL-
6-induced JAK1-STAT3 signaling in primary mouse hepatocytes
(Figure 3A). Assuming the law of mass-action kinetics, we
translated the previously established molecular interactions
(Heinrich et al., 2003) in response to IL-6 into a set of ODEs. Two
compartments were modeled to describe the shuttling of STAT3
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FIGURE 3 | Mathematical model of IL-6-induced JAK1-STAT3 signaling and model calibration with time-resolved signaling data. (A) The ODE-based model is
represented as process diagram (Kitano et al., 2005). Individual reactions of species (arrows) can be induced (circle-headed lines) or inhibited (bar-headed lines).
Dashed line borders highlight active species. AppRNA is representative for the different intermediate/late APP mRNAs Fgg, Hamp, Il33, Apcs, Hp, and Hpx. The
production of cytoplasmic Socs3 and APP mRNAs was modeled using a delay (τ ), corresponding to five additional processing steps of intermediate nuclear RNA
species. Inhibitors are shown in red color. ActD, actinomycin D; Prefix p, phosphorylated species; Prefix n, nuclear species. (B) Primary mouse hepatocytes were
treated with 40 ng/mL of hIL-6 and lysed for protein or RNA isolation at indicated time points. Phosphorylated JAK1, gp130, and STAT3 were measured using
quantitative immunoblotting preceded by immunoprecipitation to enrich for the target proteins. Recombinant calibrator proteins were used for normalization. (C)
Primary mouse hepatocytes were treated with 40 ng/mL of hIL-6 for 18min, lysed and subject to immunoprecipitation. Enriched proteins were separated by
SDS-PAGE, in-gel digested, and analyzed by mass spectrometry to determine the degree of Tyr-705 phosphorylation of STAT3. (D) Example widefield fluorescent
microscopic images of primary hepatocytes from mKate2-STAT3 mice unstimulated (left panel) or stimulated with 500 ng/mL hIL-6 for 25min (right panel). White
arrows indicate positions of nuclei. The ratio of nuclear to cytoplasmic mKate2-STAT3 was determined by live-cell imaging in 20 hepatocytes isolated from
mKate2-STAT3 heterozygous mice 10min prior to and 25min after stimulation with hIL-6 (500 ng/mL). (E) Primary mouse hepatocytes were treated with 40 ng/mL of
hIL-6 and lysed for RNA isolation at indicated time points. Socs3 mRNA was quantified by qRT-PCR (n = 3). Filled circles: experimental data; solid lines: model
trajectories. Dashed lines indicate the measurement noise as estimated by the error model. a.u., arbitrary units. For additional experimental data used for model
calibration see Appendix Figures S26–S81. In total, the model was calibrated with 3090 data points.
between cytoplasm and nucleus, as well as the nuclear export
of newly synthesized mRNAs. The model contained four input
variables: IL-6, Ruxolitinib, Stattic, and actinomycin D (ActD).
Based on immunoassays of human IL-6 in mouse hepatocyte
supernatants (Appendix Figure S2), constant IL-6 concentrations
and complete removal of ligand after stimulation pulses were
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assumed. Because Ruxolitinib was reported to have a plasma half-
life of ∼3 h in humans (Shi et al., 2011), Ruxolitinib degradation
was included in the model. Considering that inhibition by Stattic
is irreversible, its concentrations were modeled as constant.
The temporal evolution of the dynamic variables was described
by 25 ODEs, the detailed steps were as follows (Figure 3A):
gp130 and JAK1 were described to be pre-associated (Behrmann
et al., 2004) and were modeled as one complex JAK1_gp130
with different activation states, as described previously for
the interaction of JAK2 with the erythropoietin receptor
(Bachmann et al., 2011). The alpha receptor subunit IL-6R
was not considered in the model, because it is not directly
involved in the dynamic phosphorylation events that initiate
IL-6 signaling (Taga et al., 1989). IL-6 promotes activation and
phosphorylation of JAK1, causing generation of the species
pJAK1_gp130. Additionally, there is also a low level of basal
activation. Subsequently, also gp130 is phosphorylated by JAK1
to create the fully activated receptor complex pJAK1_pgp130.
Stimulus-independent negative regulatory mechanisms at the
receptor level, as reported for JAK1 (Simoncic et al., 2002;
Lehmann et al., 2003), were taken into account by including
two deactivating steps. Both partly active pJAK1_gp130 and
fully active pJAK1_pgp130 are directly converted to inactive
JAK1_gp130. This simplification is based on the assumption
that dephosphorylation of gp130 and JAK1 is coupled. STAT3 is
activated by JAK1 only after docking to phosphorylated gp130
(Lutticken et al., 1994; Stahl et al., 1995; Yamanaka et al., 1996).
Thus, double-phosphorylated pJAK1_pgp130 mediates STAT3
activation. The species pSTAT3 represents phosphorylated,
active, and dimeric STAT3. A separate dimerization step was
neglected, because the oligomerization state of STAT3 was not
assessed by experiments. Active, dimeric pSTAT3 subsequently
translocates to the nuclear compartment, and npSTAT3 promotes
transcription of Socs3 and APP genes. The generation of
cytoplasmic RNA was modeled including a delay (τ ; MacDonald,
1976; Bachmann et al., 2011) for both Socs3 and APP genes to
account for processing and nuclear export of these early-induced
transcripts. Based on repeated profile likelihood analysis, we
concluded that Socs3, Cxcl10, Fgg, Il33, Hp, and Hpx required
an explicit delay in the model to describe the available data,
while Apcs and Hamp did not. Socs3 was expressed earlier
than any of the APP genes. For the APP genes, Cxcl10
had the shortest delay, followed by Fgg. The other APP
genes exhibited slower dynamics (see Appendix Figure S24).
Cytoplasmic Socs3RNA promotes synthesis of SOCS3. SOCS3
inhibits the signaling pathway by increasing degradation of
the receptor complex as well as inhibiting phosphorylation of
STAT3 by the fully activated receptor complex (Starr et al.,
1997; Babon et al., 2012; Kershaw et al., 2013). Therefore,
SOCS3 enhances degradation of all receptor states and inhibits
the STAT3-activating reaction converting STAT3 to pSTAT3.
Production of APP proteins was not assessed experimentally
and was thus not considered in the model. The target RNA
and protein species Socs3RNA, SOCS3, and Cxcl10/AppRNA are
furthermore subject to degradation.
Deactivation of nuclear STAT3 was suggested to be mediated
by phosphatases (Yamamoto et al., 2002). A combined
dephosphorylation and dissociation step was therefore modeled
in the nuclear compartment, converting dimeric, active
npSTAT3 to monomeric, inactive nSTAT3. Based on model
identifiability analysis, it was concluded that dephosphorylation
and dissociation of STAT3 in the nucleus is very fast. Therefore,
npSTAT3 was not considered as a state variable, but modeled
proportional to the cytoplasmic concentration of pSTAT3
(see Appendix for more information). STAT3 was shown
to continuously shuttle between cytoplasm and nucleus
independent of its activation state (Liu et al., 2005; Reich and Liu,
2006). Accordingly, we allowed nuclear import for both, inactive
STAT3 and active pSTAT3, while only inactive nSTAT3 can be
exported back to the cytoplasm. The previously determined
(Mueller et al., 2015) ratio of cytoplasmic to nuclear volume
of primary mouse hepatocytes (12.67/0.5 pL, for frequently
binucleated hepatocytes) facilitated modeling of concentration
changes due to inter-compartmental transport processes.
The pathway inhibitors Ruxolitinib and Stattic were
incorporated into the model according to their published
molecular modes of action. The JAK inhibitor Ruxolitinib
(Lin et al., 2009; Quintas-Cardama et al., 2010) negatively
influences JAK1-dependent reactions in the model, specifically
the generation of pJAK1_gp130 and pJAK1_pgp130. Stattic
blocks activation and dimerization of STAT3 (Schust et al., 2006)
and therefore in our model inhibits the respective conversion of
STAT3 to pSTAT3. All transcriptional processes are furthermore
blocked by ActD.
The protein abundances of the pathway components gp130,
JAK1, STAT3, and SOCS3 were determined by quantitative
immunoblotting (Schilling et al., 2005a) according to standard
curves of recombinant calibrator proteins. The determined
number of molecules per cell (Appendix Figure S3) provided
the absolute scale for model predictions of those specific states.
Remaining unknown model parameters were estimated based on
time- and dose-dependent experimental data, as described in the
following sections.
Model Calibration with Time-Resolved
Signaling and Gene Expression Data
The mathematical model depicted in Figure 3A was calibrated
with quantitative experimental data describing the time-resolved
dynamics of IL-6-induced JAK1-STAT3 signaling in primary
mouse hepatocytes. Cells were treated with hIL-6 for up to
120min in a continuous or pulsed manner. The levels of
phosphorylated and total protein species were measured by
quantitative immunoblotting (Schilling et al., 2005a), including
randomized sample loading and normalization to suitable
housekeeping proteins or, in case proteins were enriched by
immunoprecipitation, to recombinant calibrator proteins. hIL-
6-induced phosphorylation of gp130, JAK1, and STAT3 was
transient displaying a peak at around 20min. Phospho-gp130,
-JAK1, and -STAT3 subsequently declined, but did not reach
basal levels within the observed time frame (Figure 3B). Further,
SOCS3 protein expression was determined upon treatment with
different concentrations of IL-6 (Appendix Figures S43–S45)
and we observed a transient protein expression dynamic that
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resembles the mRNA expression profiles. Using quantitative
mass spectrometry (Hahn et al., 2011), we determined the site-
specific degree of Tyr-705 phosphorylation of STAT3 at the
time point of maximal activation (54.4% at 18min, 40 ng/mL
hIL-6; Figure 3C). We also quantified the nuclear translocation
of STAT3 by live-cell imaging of hepatocytes isolated from
heterozygous mKate2-STAT3 knock-in mice (Figure 3D and
Appendix Figure S11). In mKate2-STAT3 mice, the wild type
STAT3 locus is replaced by an mKate2-STAT3 knock-in reporter
gene. The expression and phosphorylation of the fusion protein
was validated by immunoblotting in primary mouse hepatocytes
that were isolated from the knock-in reporter mice and wild-
type animals (Appendix Figure S13). Cells were treated with
hIL-6 and the phosphorylation of endogenous and tagged-
STAT3 was compared. These studies showed that mKate2-STAT3
is expressed at a slightly lower level than the endogenous
protein but the phosphorylation dynamics correlated with the
phosphorylation dynamics of the endogenous STAT3. The
mKate2-STAT3 reporter mice so far have only been obtained
as heterozygous mice. For the generation of the mKate2-STAT3
reporter mice we identified seven positive ES clones and out
of these two generated germline transmission. The crossing of
the heterozygous animals resulted in 66.8% WT and 33.2%
heterozygous animals (n = 232) and these heterozygous mice
showed no phenotype, also concerning viability in comparison
to WT animals. Due to the strong autofluorescence in the
cytoplasmic compartment of primary mouse hepatocytes (see
dot-like structures in Appendix Figure S13C), we focused on
the quantification of the IL-6-induced translocation of mKate2-
STAT3 to the nucleus. In unstimulated cells, mKate2-STAT3
was equally distributed between cytoplasm and nucleus (STAT3
nuc/cyt ratio of 1), in accordance with the previously reported
continuous shuttling of STAT3 independent of its activation state
(Liu et al., 2005; Reich and Liu, 2006). We tested continuous
shuttling of STAT3 between nucleus and cytoplasm, independent
of its activation state in our initial mathematical model. However,
based on identifiability analysis (see Appendix Figure S15), we
found that export of phosphorylated STAT3 could be made
arbitrarily small and was therefore omitted from the final
model. Following hIL-6 stimulation, mKate2-STAT3 quickly
accumulated in the nucleus. At 25min (500 ng/mL hIL-6),
the nuclear mKate2-STAT3 concentration exceeded cytoplasmic
mKate2-STAT3 by a factor of 3 (STAT3 nuc/cyt ratio of ≈3;
Figure 3D). Socs3 mRNA was measured by qRT-PCR, revealing
rapid induction after IL-6 stimulation with a peak time of 40min.
Afterwards, Socs3 mRNA levels declined, but stayed elevated
throughout the observed time frame. Background Socs3 mRNA
expression in unstimulated hepatocytes did not change over time,
indicating a specific response (Figure 3E). The trajectories of the
calibrated model accurately represented the experimental data
describing multiple levels of IL-6-induced signaling (solid lines
in Figures 3B–E and Appendix Figure S9).
To validate the microarray analysis and to obtain detailed
time-resolved expression profiles, we analyzed selected
significantly regulated genes by quantitative real-time
quantitative PCR (qRT-PCR) in a time-resolved manner. In
agreement with the microarray analysis, we found Cxcl10
and Socs3 to be early-response genes. Cxcl10 was transiently
induced by hIL-6. After an initial peak at 1 h Cxcl10 expression
levels decreased below those observed in untreated cells. Socs3
expression showed a sharp peak with high amplitude at 1 h of
hIL-6 treatment. Subsequently, its levels declined but stayed
elevated up to 24 h. This is consistent with our microarray
analysis, which identified Socs3 to critically contribute to overall
regulation (Figure 2B) and to be significantly IL-6-induced at
all time points (Figure 2C). The genes Fgg, Hamp, and Il33
were induced by IL-6 and were clearly detectable from 3 to
6 h on, as shown by qRT-PCR analysis. All three genes showed
sustained activation with high expression levels up to 24 h of
IL-6 treatment, thus validating our microarray analysis which
identified Fgg, Hamp, and Il33 to be significantly regulated
at intermediate and late time points. Apcs was found to be a
late-regulated gene. qPCR-based validation revealed a steady
decrease of Apcs expression in untreated cells. IL-6 treatment
rescued this decrease and caused elevated Apcs expression at 24 h
relative to untreated cells (Figure 4 and Appendix Figure S10).
The APP genes Hp and Hpx were not significantly regulated
in our microarray analysis (Figure 2C), but have previously
been reported to be IL-6 responsive and STAT3-dependent
(Alonzi et al., 2001). qPCR analysis identified Hp and Hpx to be
late-response genes with increased expression at 24 and 48 h of
IL-6 treatment (Figure 4 and Appendix Figure S10).
Model Calibration with Dose-Dependent
Target Gene Expression Data from Normal
and Perturbed Conditions
In addition to time-resolved data, we calibrated the mathematical
model with dose-dependent expression data for the IL-6
target genes shown in Figure 5 and Appendix Figures S4,
S5. Primary mouse hepatocytes were treated with a wide
range of hIL-6 concentrations covering basal, regenerative, and
inflammatory physiological levels (Figure 1) for 1, 6, or 24 h
to capture strong expression of early, intermediate, and late
responsive genes, respectively. Based on the experimental data,
we identified the nuclear dephosphorylation rate to be high. Since
nuclear STAT3 dephosphorylation is so rapid that the level of
nuclear phosphorylated STAT3 exactly follows the cytoplasmic
concentration of phospho-STAT3, the model was reduced by one
equation.
We further identified Socs3 mRNA to respond to IL-6
treatment in a highly sensitive manner (Figure 5A). The other
early-induced gene Cxcl10 responded at 25–50 ng/mL hIL-6,
and did not reach saturation within the observed hIL-6 range.
Compared with Socs3, it thus showed lower sensitivity toward
hIL-6 (Figure 5A). In contrast, the sensitivities of intermediate
and late APP genes were similar to that of Socs3—Fgg,Hamp, Il33,
Apcs,Hp, andHpxmRNAswere induced from 1 to 10 ng/mL hIL-
6. All showed sigmoidal dose response curves and saturation at
high IL-6 concentrations (100–500 ng/mL). The dose-dependent
behavior of all target genes was accurately described by the model
(Figures 5A–C and Appendix Figure S4).
We also calibrated our model with experimental data
describing the impact of the two pathway inhibitors Ruxolitinib
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FIGURE 4 | Detailed time-resolved analysis of selected IL-6 target genes. Primary mouse hepatocytes were stimulated with hIL-6 or left untreated and RNA was
isolated at indicated time points. Target mRNA expression was analyzed by qRT-PCR (qPCR) (A Cxcl10; B Fgg, Hamp, Il33, Apcs, Hp, and Hpx). Data were
normalized to the geometric mean (Vandesompele et al., 2002) of Hprt and Tbp expression. Filled circles represent individual replicates (n = 2); solid lines are model
fits; dashed lines indicate errors estimated from the model. The expression level in the control is modeled using a monotonic spline. Additional replicate is displayed in
Appendix Figure S10.
and Stattic on dose/time-dependent Socs3 mRNA induction and
STAT3 phosphorylation dynamics in primary mouse hepatocytes
(Figure 5D). The inhibitor Stattic shows toxic effects and is
not used in the clinic. In our experiments we applied Stattic
for a maximum of 2 h to primary mouse hepatocytes to avoid
general toxicity. Though Stattic was used to calibrate the model,
experimental results with this inhibitor are only shown in the
Appendix (Appendix Figures S9, S46, S52–S53, S62–S69, S83–
S84, S89).
Inhibitor pre-treatment for 1 h caused a reduced basal level
of Socs3 mRNA and a reduced sensitivity and peak magnitude
of the dose-dependent Socs3 response upon IL-6 stimulation
(Figure 5). Socs3 expression at 1, 6, and 24 h was detectable
from 1 ng/mL hIL-6, steadily increased, and reached saturation
at 50 ng/mL hIL-6. In line with the previous observation in a
clinical trial (Shi et al., 2011), the efficacy of Ruxolitinib decreased
with increasing incubation time. The experimental data of Socs3
expression in response to hIL-6 alone or hIL-6 and Ruxolitinib
was described by the model trajectories (Figure 5D).
To summarize, the model was calibrated in two stages.
First the upstream model of IL-6 signaling was developed
and calibrated. The upstream model also termed “core model”
consists of the receptor level, the STAT3 pools and SOCS3
and is calibrated on both wild type as well as inhibitor data.
The downstream model, which consists of the APP genes, was
included in a second step. Since none of the APP genes feed
back into the system, these were parameterized separately to keep
the analyses computationally tractable. The downstream model
was parameterized while keeping the upstreammodel parameters
fixed. Parameter profile likelihood curves for all APP genes are
presented in the supplement (Appendix Figures S15–S22).
Designing Improved Ruxolitinib Treatment
Schedules
Following calibration with quantitative experimental data, our
mathematical model was able to describe IL-6-induced signaling
responses at multiple levels, including the impact of pathway
inhibitors on STAT3 (Appendix Figure S9A) and Socs3 activation
(Figure 5). We next employed the model to predict the inhibitor
impact on hIL-6 dose-dependent APP gene expression in murine
hepatocytes. In analogy to the inhibition of Socs3 mRNA
induction (Figure 5D), the model predicted that Ruxolitinb
treatment reduces sensitivity of the response for most APP
genes (Figure 6). Importantly, subsequent experimental analysis
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FIGURE 5 | Model calibration with dose-dependent target gene expression data from normal and perturbed conditions. Primary mouse hepatocytes were pre-treated
with Ruxolitinib or DMSO control for 1 h prior to hIL-6 stimulation, or left untreated. Dose-dependent analysis of target gene expression was performed by applying
0.1–500 ng/mL hIL-6. At indicated time points (1, 6, and 24 h), target mRNAs were quantified by qPCR (A Socs3 and Cxcl10; B Fgg, Hamp, and Il33; C Fgg, Hamp,
Il33, Apcs, Hp, and Hpx; D Socs3). Filled circles: log-transformed experimental data; solid lines: model trajectories. Dashed lines indicate the measurement noise as
estimated by the error model. a.u., arbitrary units. For additional replicates used for model calibration see Appendix Figure S4.
validated the model-predicted effects of Ruxolitinib treatment
on all analyzed APP genes (Figure 6 and Appendix Figure S5).
As observed previously in the case of Socs3 mRNA expression
at 1, 6, and 24 h (Figure 5D), the long-term efficacy of
Ruxolitinb in primary mouse hepatocytes was reduced in the
case of intermediate/late APP genes (Figures 6B,C and Appendix
Figures S5B,C).
To assess the suitability of different targets in reducing
the APP response, we performed a sensitivity analysis. If one
considers the APPs to be very stable, then the protein levels will
approximately be proportional to the integral of the expression
of the APP genes. We performed a Local Parameter Sensitivity
Analysis with respect to the model parameters, which is shown in
Figure 7A. Here we can observe that inhibiting production and
activation of the receptor, inhibiting the activation of STAT3 and
reducing the degradation of Socs3 (mRNA) are all predicted to
lead to additional attenuation of the APP response. To further
inhibit STAT3 activation, we decided to apply additional doses of
Ruxolitinib.
Continuous suppression of elevated IL-6-induced APP gene
expression would be required to counteract inappropriate
inflammatory responses, but Ruxolitinib-mediated reduction of
hIL-6 target gene expression in murine hepatocytes was less
effective at advanced time points (Figures 5, 6). The model
predicted that higher single doses of Ruxolitinib would lead to
larger suppression of the APP genes. However, since higher doses
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FIGURE 6 | Model prediction and experimental validation of the inhibitor impact on dose-dependent APP gene expression. Solid lines represent model predictions for
dose-dependent APP gene expression with or without Ruxolitinib pre-treatment. For experimental validation (filled circles), primary mouse hepatocytes were
pre-treated with Ruxolitinib or DMSO control for 1 h prior to hIL-6 (0.1–500 ng/mL) stimulation. APP mRNA expression was quantified at indicated time points by
qPCR (A Cxcl10; B Fgg, Hamp, and Il33; C Fgg, Hamp, Il33, Apcs, Hp, and Hpx). Dashed lines indicate the measurement noise as estimated by the error model. a.u,
arbitrary units. For additional replicates see Appendix Figure S5. For additional experimental data used for model validation see Appendix Figures S82–S88.
of the inhibitor could have detrimental side-effects, we employed
our mathematical model to design treatment schedules for
Ruxolitinib where the concentration of Ruxolitinib in the system
does not exceed a maximal dose. The aim was to continuously
suppress elevated IL-6-induced APP gene expression, while not
exceeding amaximal level of 500 ng/mLRuxolitinib. As objective,
the integral up to 24 h of the APP mRNA levels in response to
100 ng/mL hIL-6 was used as a proxy for APP expression during
inflammation. In this way, inappropriate inflammatory responses
could be counteracted without completely abrogating APP gene
expression. Ideally, continuous administration of Ruxolitinib
would be preferred. However, due to practical considerations,
we restricted the search to a maximum of three injections. The
model predicted which three Ruxolitinib doses in even time
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FIGURE 7 | Optimized inhibition of STAT3 nuclear translocation. (A) Averaged Local Parameter Sensitivity Analysis for the integrated APP response. Bars indicate
model sensitivities to a 50% perturbation in model parameter. Error bars indicate maximum and minimum sensitivity along parameter likelihood profiles. Large
perturbations were performed since we are interested in parameters that would have a substantial impact on dynamics. (B) Model predictions for Ruxolitinib
concentrations over time after single treatment with 500 nM at t = –1 h (Single), or using the optimized triple treatment scenario, including Ruxolitinib treatments at t =
0 h (500 nM), 8 h (191 nM), and 16 h (191 nM) (Triple). Arrow indicates the time window of nuclear STAT3 profiling. (C) Example widefield fluorescent microscopic
images of primary hepatocytes from mKate2-STAT3 mice during the long-term quantification of IL-6-induced mKate2-STAT3 translocation in presence or absence of
Ruxolitinib. Cells were stimulated with 100 ng/ml hIL-6 for 24 h, either treated with solvent control (DMSO), pre-treated for 1 h with 500 nM Ruxolitinib (Single
Ruxolitinib) or co-treated with 500 nM Ruxolitinib and re-treated with 191 nM at 8 and 16 h (Triple Ruxolitinib). Inhibitor treatment was performed as suggested by the
model (B). Image quantification of nuclear mKate2-STAT3 was conducted from 20 to 24 h after hIL-6 stimulation. White arrows indicate positions of nuclei.
H2B-mCerulean was used to indicate the positions of nuclei. Scale bar: 20µm. (D) Squares represent model predictions for nuclear STAT3 after treatment with the
indicated hIL-6 concentrations in combination with DMSO control, single or triple Ruxolitinib treatment. For experimental validation, primary mouse hepatocytes from
mKate2-STAT3 mice were treated accordingly with DMSO or Ruxolitinib and hIL-6. Circles represent average nuclear STAT3 measured with time-lapse microscopy
20–24 h after hIL-6 stimulation. Error bars indicate the measurement noise as estimated by the error model. a.u., arbitrary units. Data presented corresponds to the
average of at least 45 imaging fields per condition. For additional replicates see Appendix Figure S6. For additional experimental data used for model validation see
Appendix Figures S93–S98.
intervals would effectively counteract loss of the inhibitor due to
degradation (Figures 7B, 8A).
Therefore, in the presented study, the objective was to
minimize the integral of APP mRNA levels. However, we did
not use an optimization procedure as a means of determining
the treatment schedule, because it is not clear how to prioritize
the different APP genes. Instead we made response curves for
each of the APP genes and determined the ideal point via
visual inspection. Depending on which APP gene is considered
therapeutically most important, deviations from this design may
be more optimal (see section 3.7 of the Appendix). Predictions
for the integrated target gene expression at time point 24 h
furthermore revealed that applying the first treatment at t =
0 h, simultaneously with the start of IL-6 treatment, would be
superior to the previously applied pre-treatment with Ruxolitinib
at 1 h before IL-6 stimulation (Appendix Figure S8). Thus, an
optimized Ruxolitinib treatment would include three subsequent
treatments at t = 0, 8, and 16 h. Given that 500 nM Ruxolitinib
would be applied as first bolus at t = 0 h, the model predicted
that 191 nM Ruxolitinib would be required to replenish the
full inhibitor potential at each, 8 h, and 16 h. The initial dose
of 500 nM Ruxolitinib was selected based on dose response
experiments (Appendix Figures S70, S71) in primary mouse
hepatocytes and closely relates to the determined IC50.
Using two experimental readouts, namely nuclear
translocation of STAT3 as an indicator of activated STAT3,
and IL-6 target gene expression, we validated the predicted
advantage of Ruxolitinib triple treatment over the previously
applied single pre-treatment (Figures 7, 8). Compared to the
single treatment (q24h), the triple treatment (q8h) induced
a more sustained inhibitory effect, utilizing considerably
lower doses for the repetitive treatment after the initial bolus.
Primary mouse hepatocytes were either treated with a single
dose (500 nM) of Ruxolitinib at t = –1 h (Single), or with
three doses at time points t = 0 h (500 nM), 8 h (191 nM),
and 16 h (191 nM; Triple). Cells were stimulated with hIL-6
concentrations resembling basal (0 ng/mL), regenerative (7.5
ng/mL) or inflammatory (100 ng/mL) physiological levels
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FIGURE 8 | Optimized inhibition of APP gene expression in primary mouse hepatocytes. (A) Model predictions for Ruxolitinib concentrations over time after single
treatment with 500 nM at t = –1 h (Single), or using the optimized triple treatment scenario, including Ruxolitinib treatments at t = 0 h (500 nM), 8 h (191 nM), and 16 h
(191 nM) (Triple). Arrow indicates the time point of gene expression analysis. (B,C) Expression of Socs3 (B) and APP genes (C) at 24 h after inhibitor treatments as
described in (A). Squares represent model predictions and circles represents experimental data, while error bars indicate the measurement noise estimated by the
error model. a.u., arbitrary units. Dashed lines indicate the level of gene expression after triple inhibitor dosing of the cells treated with inflammatory dose of hIL-6 (100
ng/mL). Displayed are results of one biological replicate, while two more replicates are shown in Appendix Figure S7. For additional experimental data used for model
validation see Appendix Figures S89–S91.
(Figure 1). In hepatocytes derived from mKate2-STAT3 mice,
we analyzed the nuclear mKate2-STAT3 concentration within
the time frame 20–24 h (after start of IL-6 treatment) by
live-cell imaging (Figure 7C). Comparing model predictions
and experimental data for the different Ruxolitinib treatment
regimens and IL-6 concentrations revealed good agreement
between model and experiment (Figure 7D and Appendix
Figure S6): Ruxolitinib-mediated suppression of mKate2-STAT3
nuclear translocation was improved when the triple treatment
regime was applied, compared with single treatment. In wild type
hepatocytes we measured APP gene expression at 24 h. Triple
Ruxolitinib treatment lead to improved suppression of most
genes, compared with single Ruxolitinib treatment (Figure 8
and Appendix Figure S7). The effect was most obvious for Socs3,
and also recognizable for all other genes, although error bars
were partly overlapping for single and triple treatment.
Importantly, triple Ruxolitinib treatment reduced gene
expression observed at inflammatory IL-6 concentrations (100
ng/mL) to levels more closely resembling regenerative conditions
(7.5 ng/mL, DMSO control) for all genes (Figure 8 and
Appendix Figure S7). To conclude, our mathematical model and
experimental validation suggested that a triple treatment with
Ruxolitinib and not a single dose is required, when an effective
attenuation of IL-6-dependent responses in hepatocytes is
desired.
To provide a proof-of-concept that these insights, obtained
with our model based approach for primary mouse hepatocytes,
are applicable to the human system, we employed primary
human hepatocytes to compare a single bolus treatment with
the model-suggested triple dosing strategy. To mimic the
regenerative and inflammatory situation in the human system,
1.8 and 50 ng/mL hIL-6 were chosen to stimulate human
hepatocytes, assuming that the potency of human IL-6 on human
hepatocytes is comparable to that of mouse IL-6 on primary
mouse hepatocytes and by utilizing the dose response curves
shown in Figure 1D.
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The maximal tolerable dose of Ruxolitinib in healthy
volunteers was described to be 100 mg once daily, already
inducing severe side effects as neutropenia (Shi et al., 2011).
This amount corresponds to a concentration of 65 nM assuming
an average blood volume of 5 L per human body. The dose-
dependent effect of Ruxolitinib on STAT3 phosphorylation in
primary human hepatocytes revealed that 50 nM of the inhibitor
is in the range of the IC50 determined in cells co-treated with
hIL-6 (1 or 10 ng/mL) and increasing doses of Ruxolitinib
(up to 5,000 nM; Appendix Figure 12). Hence, primary human
hepatocytes show an increased sensitivity toward the treatment
with Ruxolitinib in comparison to primary mouse hepatocytes.
Therefore, we reduced the initial dose of Ruxolitinib from 500
nM as applied in primary mouse hepatocytes to 50 nM for
primary human hepatocytes (Figure 9A) and the subsequent
second and third dosing of 191 nM Ruxolitinib was reduced to
19 nM accordingly.
We measured the expression of the four previously analyzed
genes SOCS3 (Figure 9B), HAMP, HP, and FGG (Figure 9C),
which are established as IL-6 responsive genes both in mouse
and human. Additionally the IL-6 induced expression of CRP
(Figure 9C) was examined in primary human hepatocytes
due to its routine clinical determination as an indicator of
inflammatory responses. For several of the genes of interest
almost maximal expression was already achieved with the lower
hIL-6 concentration applied suggesting that their expression
saturated at lower IL-6 doses in human hepatocytes compared
to murine hepatocytes. In line with the model-based insights, the
triple Ruxolitinib treatment at equivalent time intervals was again
more effective compared to the single treatment to suppress IL-
6 induced SOCS3 and APP gene expression in primary human
hepatocytes, confirming our concept.
DISCUSSION
While IL-6 has repeatedly been suggested to contribute to
inflammatory or malignant diseases, targeting this central
mediator needs to be carefully evaluated to maintain its beneficial
regenerative functions (Hunter and Jones, 2015). Here we
developed a mathematical model of IL-6-induced JAK1-STAT3
signaling in primary mouse hepatocytes, which adequately
predicted how inflammatory gene expression could be reduced
to regenerative levels by optimized Ruxolitinib treatment.
Determination of in vivo circulating and the IL-6
concentrations during liver regeneration and inflammation
enabled to study IL-6 signaling pathway activation within
relevant IL-6 concentration ranges. Determined serum levels
agree with previously reported values after PHx (1–2 ng/mL;
Nechemia-Arbely et al., 2011; Yin et al., 2011) and LPS
treatment (175 ng/mL; Piao et al., 2013) of mice. Importantly,
simultaneous analysis of samples from PHx- and LPS-treated
mice, as performed here, enabled direct comparison of the
regenerative and inflammatory scenarios. Thus, we established
distinct IL-6 concentration ranges during liver regeneration and
inflammation. By quantifying the hepatic IL-6 concentrations,
we provide evidence that IL-6 accumulates in the hepatocyte
microenvironment after PHx (serum: 1.4 ng/mL, local: 6.8–7.9
ng/mL). This is likely a result of an increased IL-6 secretion
by Kupffer cells (Aldeguer et al., 2002) to promote an efficient
regenerative response. In contrast, IL-6 levels were similar in
serum and hepatocyte microenvironment after LPS injection
(serum: 201.8 ng/mL, local: 28.1–500 ng/mL). Local hepatic
IL-6 levels following PHx in liver tissues at mRNA and protein
level were reported previously (Yin et al., 2011). However, the
published IL-6 levels represent both, extra- and intracellular
IL-6, and are thus not directly equivalent to IL-6 levels that
actively stimulate hepatocytes. Here we inferred the IL-6
concentrations from STAT3 phosphorylation levels in whole
liver lysates. Because IL-6 appears to be the main inducer of
STAT3 activation in hepatocytes (Cressman et al., 1996), the
major hepatic cell type, this approach provides a good estimate
of IL-6 concentrations in the hepatocytes’ microenvironment.
To exclude the contribution of other cytokines to the
activation of STAT3, we performed a qPCR analysis of Il11, Osm,
and Il22mRNA expression in liver lysates from LPS or PHx mice
(Appendix Figure S14). In these experiments we did not observe
an elevation of the mRNAs encoding these cytokines within
the time frame of maximal STAT3 phosphorylation detected in
the liver lysates from the corresponding mice, at 1 h in LPS
treated mice and at 2 h in hepatectomized mice, respectively
(Figure 1B). On the contrary a very rapid induction of Il6mRNA
was detected particularly in response to LPS injection that was
already maximal after 1 h of LPS injection (Appendix Figure S14)
and coincided with maximal STAT3 phosphorylation observed
at 1 h post treatment (Figure 1B). These results are in line with
the studies of Ren et al. reporting that there is no statistically
significant increase of Il22 mRNA in response to hepatectomy,
but rather an increase of IL-22 protein is observed in the serum
at late time points post hepatectomy starting at 6 h post treatment
with a peak at 12 h (Ren et al., 2010). Others observed a peak
of Il22 mRNA induction in the liver at ∼3 h post hepatectomy
(Rao et al., 2014) or 4 h after LPS injection (Wegenka et al., 2007)
and thus much later than the rapid maximal phosphorylation of
STAT3 we observed in our study in the liver of hepatectomized or
LPS treated mice. Furthermore, 4 h post LPS injection peak levels
of IL-22 were detected by ELISA measurements corresponding
to ∼600 pg/mL (Dumoutier et al., 2011) whereas, in agreement
with the study by Wegenka et al., we observed already at 2 h
post LPS injection a peak concentration of IL-6 in the serum of
201.8 ng/mL suggesting that the induction of IL-6 in response
to LPS is more rapid and more than two orders of magnitude
higher compared to IL-22. Further, a major contribution of IL-
10 to the early activation of STAT3 and the induction of the
acute phase response in hepatocytes appears unlikely. Although
it has been observed that the expression of Il10 mRNA can be
induced by PHx (Yin et al., 2011), the ability of IL-10 to induce
signaling via JAK1/STAT3 appears primarily restricted to cells of
the immune system, such as macrophages and dendritic cells, due
to the expression of the IL-10 receptor that is most prominent in
these cell types (Murray, 2006; Sabat et al., 2010). In light of these
observations we propose that IL-6 is the mediator of immediate
early responses in hepatocytes involving STAT3 phosphorylation
during liver regeneration whereas other cytokines such as IL-22
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FIGURE 9 | Optimized inhibition of APP gene expression in primary human hepatocytes. (A) Model predictions for Ruxolitinib concentrations over time after single
treatment with 50 nM at t = –1 h (Single), or using the optimized triple treatment scenario, including Ruxolitinib treatments at t = 0 h (50 nM), 8 h (19 nM), and 16 h (19
nM) (Triple). Arrow indicates the time point of gene expression analysis. (B,C) Expression of SOCS3 (B) and APP genes (C) at 24 h after inhibitor treatments as
described in (A). Data from primary human hepatocytes of three different donors are shown as mean ± SEM.
or IL-10 may contribute to STAT3 phosphorylation at later time
points or in other cell types than hepatocytes.
Because the hepatic acute phase response is largely regulated
at the transcriptional level (Andus et al., 1988; Heinrich et al.,
1990), we studied IL-6-induced mRNA expression changes in
primary mouse hepatocytes. We established the time-dependent
regulation of previously known IL-6 targets including Socs3
(Starr et al., 1997), Hamp (Wrighting and Andrews, 2006;
Pietrangelo et al., 2007), Fgg, Apcs, Hp, Hpx (Alonzi et al., 2001)
as well as of two less well-established targets, Cxcl10 and Il33.
IL-6-induced genes were grouped into early, intermediate, and
late responsive genes, according to their expression levels at 1, 6,
and 24 h after IL-6 stimulation. CXCL10was described previously
to be secreted by macrophages in an IL-6/STAT3-dependent
manner (Xu et al., 2012, 2015). In the context of hepatitis C
virus infection, CXCL10 was suggested to contribute to persistent
liver inflammation and fibrosis (Zeremski et al., 2008, 2009;
Brownell and Polyak, 2013). Here, we provide evidence that IL-
6 stimulated hepatocytes might be a crucial source for CXCL10.
In line with the reports by Zeremski et al. (2008, 2009) and
Brownell and Polyak (2013), linking CXCL10 and inflammation,
Cxcl10 mRNA was selectively induced by inflammatory IL-6
concentrations, while all other analyzed target genes responded
to both, regenerative and inflammatory IL-6 stimuli (Figure 5).
In addition to Cxcl10, we identified Il33 to be expressed in
response to IL-6 in primary mouse hepatocytes. This IL-1-like
cytokine (Schmitz et al., 2005) was described to be induced in
fibrotic livers, and hepatic stellate cells were suggested as major
IL-33 producer in this context (Marvie et al., 2010). Our results
indicate that also hepatocytes might produce IL-33. We observed
strong and sustained induction of Il33 mRNA (Figure 4), which
together with its suggested role of IL-33 as a general alarm
signal (Miller, 2011), highlight this gene as an interesting IL-
6 target and APP gene in hepatocytes. Both, CXCL10 and
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IL-33 secretion by hepatocytes should be investigated in the
future to better understand the potential link between IL-6 and
chronic inflammation. By acting on T-cells and innate immune
cells (Miller, 2011; Brownell and Polyak, 2013), CXCL10 and
IL-33 might contribute to the amplification of inflammatory
responses.
Signal processing in hepatocytes translates extracellular IL-6
levels to JAK1-STAT3 signaling dynamics and to changes in gene
expression. We could quantitatively link these different levels by
implementing a mathematical model, which not only described
experimentally observed signaling dynamics, but also the impact
of the pathway inhibitors Ruxolitinib and Stattic on STAT3 and
its target gene activation. While previous mathematical models
of IL-6 signaling incorporated IL-6-induced JAK-STAT as well
as mitogen-activated protein kinase (MAPK) cascades (Singh
et al., 2006; Moya et al., 2011; Xu et al., 2015), we focused
our model scope on the JAK-STAT pathway, which according
to Dierssen et al. is relevant for IL-6-induced APP expression
whereas MAPK activation is dispensable (Dierssen et al., 2008).
To obtain a predictive mathematical model, the relation of
considered species and experimentally measured components as
well as the amount of experimental data needs to be appropriate
(Aldridge et al., 2006; Bachmann et al., 2012). Compared to the
earlier approaches (Singh et al., 2006; Moya et al., 2011; Xu et al.,
2015) that partly relied on literature derived parameter values
obtained from different cell types and stimulating agents, the
amount of experimental data used for calibration and validation
of the model presented here is more extensive. As an example,
we assessed the protein concentration of key players of the
signal transduction pathway in primary mouse hepatocytes. The
obtained value for STAT3 is in good agreement with recently
published data from a mass spectrometry approach to determine
molecules per cell in primary human hepatocytes (Wisniewski
et al., 2016). For the presented study an extensive amount of
experimental data was generated using different technologies
ranging from quantitative immunoblotting, multiplexed bead-
based arrays and quantitative mass spectrometry to qRT- PCR
and microarray analysis in order to assess the dynamics of signal
transduction and target gene expression. Whereas quantitative
immunoblotting, multiplexed bead-based arrays, and qRT-PCR
permit very detailed time-resolved analysis, omics technologies
will be increasingly employed for quantitative analysis and to
facilitate the link to primary patient material (Iwamoto et al.,
2016; Adlung et al., 2017).
The nuclear translocation of STAT3 is a crucial aspect of
signal transduction in response to IL-6 stimulation. Therefore the
determination of the spatial dynamics of STAT3 and inclusion
in the mathematical model are of importance. To quantitatively
assess this behavior in the context of primary hepatocytes
expressing endogenous amounts of fluorescently labeled STAT3,
we generated the mKate2-STAT3 reporter mouse line. Since
the fluorescently labeled STAT3 was created as knock-in into
the endogenous STAT3 locus, its expression should mirror the
expression of STAT3 in different organs. Therefore, the reporter
mouse model offers a wide range of possible applications to study
STAT3 in multiple organs and could especially be useful to track
the dynamics of STAT3 at the single cell level.
We established a mathematical representation of the
signaling network and could confirm its high predictive power
by experimentally validating previously untested scenarios.
Specifically, a model-predicted treatment with a high initial
bolus and two following lower doses is necessary for a long-
term effect of the clinically applied inhibitor Ruxolitinib, thus
counteracting its rapidmetabolism (Shilling et al., 2010) resulting
in its short half-life (Shi et al., 2011).
Multiple-dose Ruxolitinib treatment with equal doses was
shown earlier to have a more sustained effect on STAT3 signaling,
compared with single treatment (Shi et al., 2011). Importantly,
Shi et al. found negligible accumulation of Ruxolitinib after
multiple doses, thus minimizing the risk of potential side effects.
A twice-daily dosing regimen was furthermore successfully
applied in the treatment of myelofibrosis patients (Verstovsek
et al., 2012). Notably, previous treatment planning was based
on preclinical data and empirical results from clinical trials
(Quintas-Cardama et al., 2010; Shi et al., 2011).
While the single treatment with Ruxolitinib did reduce
the APP response after treatment with IL-6, more sustained
inhibition may still be of importance, but an increase in dose
is not desirable due to harmful side-effects such as neutropenia
(Shi et al., 2011). If we consider the parameter sensitivity analysis
(see Figure 7A), we can observe that additional alternatives
exist to further suppress the APP response. One option would
be to selectively reduce the Socs3 mRNA degradation rate to
benefit from synergistic effects between the pathway’s natural
inhibitor SOCS3 and the drug Ruxolitinib. However, since
selective inhibition of mRNA degradation for one specific mRNA
species may not be feasible, a more practical option could be to
reduce receptor accessibility. This may be achieved by additional
application of a therapeutic antibody against the IL-6 receptor.
In silico analyses, based on mathematical models represent
promising approaches to optimally exploit an inhibitor’s
potential and pre-assess drug safety, prior to testing the drug
in patients or healthy individuals. Our established mathematical
model represents a starting point for further adaptation to the
human system, and could facilitate in silico drug treatment
planning in the future.
MATERIALS AND METHODS
Chemicals
Chemicals were purchased from Sigma-Aldrich, if not specified
otherwise.
Partial Hepatectomy (PHx) and LPS
Treatments of Mice
C57BL/6J mice (Janvier) were housed in the animal facility of
the Heinrich-Heine-University of Düsseldorf under a constant
light/dark cycle, maintained on a standard mouse diet, and
allowed ad libitum access to food and water. Male, 8–12
week old mice were used for PHx and LPS experiments.
Procedures were approved by the North Rhine-Westphalia State
Agency for Nature, Environment and Consumer Protection
(reference number 87-51.04.2010.A279 for PHx experiments;
reference number 84-02.04.2011.A096 for LPS injections). PHx
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was performed based on the standardized procedure described by
Mitchell and Willenbring (2008). Mice were anesthetized using
isoflurane (Abott) and received 5 mg/kg body weight carprofen
(Pfizer) subcutaneously for analgesia during surgery and the
three following days. During the operation, mice were placed on
a warming pad. The abdominal cavity was opened applying a 3
cm incision. The left lateral liver lobe was removed by applying
a ligature (time point 0 h) close to the base of the lobe followed
by cutting the tied lobe just above the suture. A second ligature
was placed around the median lobe above the gall bladder but
with at least 2mm distance to the suprahepatic vena cava. The
tied median lobe including gall bladder was then resected by
cutting just above the suture. Ringer’s lactate solution (B.Braun)
was applied to detect possible abdominal bleeding which, if
present, was stopped before closing peritoneum and skin by
over-and-over sutures. The weight of the resected left lateral and
median liver lobes was determined. Mice were monitored during
awakening and the following days including daily determination
of body weight. Sham surgeries were performed analogous to
PHx, but without placing ligatures and liver lobe removal. Liver
lobes were moved as during PHx operations (time point 0 h).
For LPS-injections, LPS (Escherichia coli 0111:B4) was
dissolved in 0.9% NaCl (Baxter) and injected intraperitoneally at
a concentration of 1 µg/g body weight. At indicated time points
after Sham/PHx surgery or LPS-injection mice were anesthetized
as outlined above and blood was collected from the vena cava.
After clotting, blood serum was obtained by two centrifugation
steps at 10,000 × g for 10min. Livers were perfused in an
antegrade direction with cold PBS (Biochrom) supplemented
with 0.1mM Na3VO4 until perfusate was clear. Livers were
extracted from mice, flash frozen in liquid nitrogen, and stored
at –80◦C.
Isolation of Primary Mouse Hepatocytes
Primary mouse hepatocyte isolation was performed in a
standardized way according to Klingmuller et al. (2006)
or according to the refined protocol described by Huard
et al. (2012). C57BL/6N mice (Charles River) were housed
at the DKFZ animal facility under a constant light/dark
cycle, maintained on a standard mouse diet, and allowed ad
libitum access to food and water. Hepatocyte isolation from
mice was approved by the governmental review committee
on animal care of the state Baden-Württemberg, Germany
(reference number A24/10). For standard time course and
dose response experiments, 2 × 106 cells were seeded in 6
cm collagen I-coated tissue culture plates (BD Biosciences)
in 2mL of adhesion medium [phenol red-free Williams E
medium (Biochrom) containing 10% (v/v) fetal bovine serum
(Life Technologies), 0.1µM dexamethasone, 10µg/mL insulin,
2mM L-glutamine and 1% (v/v) penicillin/streptomycin 100
× (both Life Technologies)]. Cells were maintained at 37◦C,
5% CO2, and 95% relative humidity. After 4 h of adhesion,
unattached hepatocytes were removed by washing 3×withDPBS
(PAN Biotech) followed by over-night cultivation (14–16 h) in
pre-starvation medium [phenol red-free Williams E medium
containing 0.1µM dexamethasone, 2mM L-glutamine, and 1%
(v/v) penicillin/streptomycin 100 ×]. The next day cells were
washed 3×with DPBS and cultured for 5 h in starvationmedium
[phenol red-free Williams E medium supplemented with 2mM
L-glutamine, 1% (v/v) penicillin/streptomycin 100× and 25mM
HEPES] prior to inhibitor/IL-6 treatment. Hepatocytes were
always isolated as described and cultivated on collagen I-coated
tissue culture plates (BD Biosciences). Differing cell numbers and
plate formats or extended pre-starvation periods are indicated in
respective methods sections.
Isolation of Primary Human Hepatocytes
The isolation of primary human hepatocytes was performed
as described in Iwamoto et al. (2016). For the isolation of
the primary human hepatocytes macroscopically healthy tissue
was used that originated from resected tumor-free tissue from
human livers of three patients (Donor 1: age 65, gender male,
disease hepatocellular carcinoma with cirrhosis and diabetes;
Donor 2: age 68, gender male, disease hepatocellular carcinoma
with nutritive-toxic liver cirrhosis, diabetes, arterial hypertonia;
Donor 3: age 78, gender female, disease Klatskin tumor
with Steatosis hepatis grade 2, diabetes, arterial hypertonia).
Informed consent of the patients was obtained according to
the ethical guidelines of the Medical Faculty of the University
of Leipzig. Primary human hepatocytes were shipped as cell
suspension in ChillProtec Plus (Biochrom) on ice overnight
to DKFZ Heidelberg. Primary human hepatocytes were serum-
and dexamethasone-depleted and cultivated using the protocol
described above for primary mouse hepatocytes, with an
adhesion time of 6 h.
Inhibitor and IL-6 Treatments
The STAT3 inhibitor Stattic (Merck Millipore) and the JAK
inhibitor Ruxolitinib (Cayman Chemical) were reconstituted in
DMSO and primary mouse hepatocytes were pre-treated with
the indicated concentrations of inhibitors or DMSO control for
1 h prior to IL-6 stimulation. Actinomycin D was dissolved in
DMSO and cells were pre-treated with 1µg/mL actinomycin D
or DMSO control for 10min prior to addition of IL-6. Human
recombinant hIL-6 was manufactured as described in Vandam
et al. (1993). Mouse IL-6 was purchased from R & D (406-ML-
005). IL-6 stock solutions were diluted in starvation medium and
cells were stimulated with the indicated IL-6 concentrations and
time spans. Pulsed stimulation was achieved by carefully washing
the cells 3 × with starvation medium to remove unbound IL-6
ligand at indicated time points. For treatment durations of up
to 2 h, cells were kept at 37◦C in a bench-top incubator after
inhibitor and/or IL-6 stimulation. During long-term experiments
cells were incubated at 37◦C, 5%CO2, and 95% relative humidity.
Immunoassays for the Quantification of
IL-6 Levels in Serum and Hepatocyte
Supernatants
IL-6 concentrations in mouse serum were quantified using the
MILLIPLEX mouse cytokine/chemokine magnetic bead panel
(EMD Millipore) according to the manufacturer’s instructions.
Samples were incubated with antibody-coupled beads overnight.
Washing procedures were performed using the ELx405 wash
station (BioTek) and fluorescence intensity was detected by a
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Luminex 200 System in combination with xPONENT Software
version 3.1 (Millipore). IL-6 concentrations in hepatocyte
supernatants were measured using the Bio-Plex Pro human IL-
6 assay in combination with the Bio-Plex Pro reagent kit (both
Bio-Rad) according to themanufacturer’s instructions. A dilution
series of the recombinant human IL-6 used for stimulation
was used as standard curve. Washing was performed using
the Bio-Plex Pro II wash station (Bio-Rad) and fluorescence
intensity was acquired using the Bio-Plex 200 system and Bio-
Plex Manager software version 6.1 (both Bio-Rad). Alternatively,
IL-6 concentrations in hepatocyte supernatants were determined
using the QuantikineHuman IL-6 Immunoassay (R&D Systems).
Stabilization of ligand in medium samples was achieved by
supplementing 450 µL conditioned medium with 50 µL of
40mMHCl and 10 mg/mL BSA.
Quantitative Immunoblotting
At precise time points cells were lysed in 1% Nonidet P-40 lysis
buffer [1% (v/v) Nonidet P-40 (Roche Applied Sciences), 150mM
NaCl, 20mMTris pH 7.4, 10mMNaF, 1mMEDTA (Applichem)
pH 8.0, 1mM ZnCl2 pH 4.0, 1mM MgCl2, 1mM Na3VO4,
10% glycerol; freshly supplemented with 2µg/mL aprotinin and
200µg/mL 4-(2-aminoethyl)benzenesulfonylfluorid] and cleared
lysates were either directly subjected to SDS-PAGE or used
for immunoprecipitations. For cellular fractionation, cytosolic
extracts were prepared as described above using Nonidet P-40
lysis buffer. Pelleted nuclei were washed once with Nonidet P-40
lysis buffer and then resuspended in nuclear lysis buffer [420mM
NaCl, 20mM HEPES pH 7.9, 10mM KCl, 1mM EDTA pH 8.0,
1mM Na3VO4, 10% (v/v) glycerol) supplemented with 2µg/mL
aprotinin, 200µg/mL 4-(2-aminoethyl)benzenesulfonylfluorid
and 1mM DTT]. Nuclei were lysed by pulsed sonication and
cleared nuclear lysates were subjected to SDS-PAGE or used for
immunoprecipitations. Quality of fractionation was checked by
correct subcellular localization of marker proteins Sp1 (nuclear;
Santa Cruz Biotechnology, #sc-59) and Eps15 (cytosolic; Santa
Cruz Biotechnology, #sc-534).
Protein concentrations of lysates were quantified by BCA
assay (Pierce, Thermo Scientific). To immunoprecipitate target
proteins, lysates were incubated with anti-gp130 (C20, Santa
Cruz Biotechnology, #sc-655), anti-JAK1 serum (Upstate/Merck
Millipore, #06-272), anti-STAT3 (Cell Signaling Technology,
#9132) or anti-SOCS3 (clone 1B2, Invitrogen, #37-7200)
antibodies, protein-A sepharose (GE Healthcare), and
recombinant calibrator proteins. For immunoprecipitation
experiments the following recombinant proteins were
added as calibrator proteins directly to the cell lysates to
enable normalization of immunoblot data: Glutathione S-
transferase (GST)-tagged gp1301N (cytoplasmic domain);
GST-STAT3 (full length protein) and Streptavidin binding
protein (SBP)-tagged SOCS3 (full length protein). Precipitated
proteins and cytoplasmic or nuclear lysates (40–50 µg) were
resolved by 10% SDS-polyacrylamide gel electrophoresis and
transferred to nitrocellulose membranes according to previously
described recommendations for quantitative immunoblotting
(Schilling et al., 2005a). Membranes were incubated with anti-
phosphotyrosine antibody (4G10, Upstate/Merck Millipore, #05
321) to detect the phosphorylated forms of gp130 and JAK1,
anti-gp130 (C20, Santa Cruz Biotechnology, #sc-655), anti-JAK1
(Cell Signaling Technologies, #3332), anti-phospho-STAT3, anti-
STAT3 (both Cell Signaling Technologies, 3E2 #9138, #9132) and
anti-SOCS3 (Abcam, #ab16030) antibodies. For normalization in
cell lysate samples, anti-calnexin and anti-Hsc70 (both Stressgen,
#ADI-SPA-860, #SPA-816) antibodies were applied. Nuclear
marker proteins were detected by anti-Sp1 and anti-Eps15
antibodies (both Santa Cruz, #sc-59, #sc-534). Horseradish
peroxidase coupled secondary antibodies (anti-mouse, anti-
rabbit, protein A) were derived from GE Healthcare. Antibodies
were removed by β-mercaptoethanol/SDS-treatment prior
to re-probing for a different protein. Phosphorylated species
were detected first, followed by total proteins and normalizers.
Proteins were visualized using enhanced chemiluminescence
substrate (GE Healthcare) and signals were detected using a
CCD camera (LumiImager F1, Roche; or ImagequantLAS4000,
GE Healthcare). For band quantification, LumiAnalyst 3.1
(Roche) or ImagequantTL (GE Healthcare) software was used.
Quantitative immunoblotting data were either processed using
GELINSPECTOR software (Schilling et al., 2005b) or directly used
for mathematical modeling.
Bead-Based Immunoassays for the
Analysis of STAT3 Activation
IL-6 concentrations in the liver were determined by measuring
STAT3 activation as read-out. Livers from Sham/PHx or
NaCl/LPS-treated mice as well as primary mouse hepatocytes
were lysed in total cell lysis buffer [136mM NaCl, 20mM Tris-
HCl, 10% glycerol, 2mM EDTA, 50mM β-glycerophosphate,
20mM sodium pyrophosphate, 1mM Na3VO4, 1% Triton X-
100, 0.2% SDS, 1 tablet/10mL completeMini EDTA-free protease
inhibitors (Roche), pH 7.4]. For other experiments, hepatocytes
were lysed using Nonidet P-40 lysis buffer as described above.
Livers were homogenized using a microcentrifuge tube-pestle
followed by passing through QIAshredder (Qiagen) columns.
Cleared liver and hepatocyte lysates were subjected to BCA assay
(Pierce, Thermo Scientific) to determine protein concentrations.
Relative phospho-STAT3 levels were quantified using the bead-
based Bio-Plex phospho-STAT3 (Tyr-705) assay in combination
with the Bio-Plex phosphoprotein detection reagent kit, or using
themagnetic bead-based Bio-Plex Pro phospho-STAT3 (Tyr-705)
set (all Bio-Rad) according to the manufacturer’s instructions.
Equal amounts of protein (16.67 µg/well or 10 µg/well in a 96-
well plate format) were incubated with antibody-coupled beads
overnight. For washing steps, the Bio-Plex Pro II wash station
(Bio-Rad) was used. The fluorescence intensity corresponding
to relative phospho-STAT3 levels was acquired using the Bio-
Plex 200 system and Bio-Plex Manager software version 6.1 (both
Bio-Rad).
Quantification of Target Gene Expression
by Quantitative Real-Time PCR (qRT-PCR)
Cells were collected in RLT Plus lysis buffer and lysates
were homogenized using QIAshredder spin columns (both
Qiagen). Homogenized lysates were immediately placed on
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dry-ice and stored at –80◦C until RNA isolation. RNA was
extracted using the RNeasy Plus Mini Kit (Qiagen) according
to the manufacturer’s instructions. Reverse transcription was
performed using either the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems) or the QuantiTect
Reverse Transcription Kit (Qiagen). Diluted cDNA was analyzed
applying the Universal ProbeLibrary System on a LightCycler 480
(both Roche), cycling conditions can be found in Appendix Table
S2. Relative mRNA concentrations were calculated according to
a cDNA dilution series with the Absolute Quantification Second
Derivative Maximum method of the LightCycler 480 Basic
Software (Roche). Target mRNA concentrations were normalized
to the geometric mean of Hprt/Tbp concentrations or to Hprt
concentrations. Primer/probe combinations were designed using
the Universal ProbeLibrary Assay Design Center (Roche) and are
listed in Appendix Table S3.
Microarray Experiment
Primary mouse hepatocytes (2 × 106 cells per 10 cm dish)
were cultivated in pre-starvation medium for 24 h before ligand
treatment. hIL-6 was added directly to cells in pre-starvation
medium at 40 ng/mL and untreated or IL-6-treated samples
were collected at time points 0 (4 replicates), 0.5, 2, 4, 8, 16,
24, 32 h (2 replicates each). Results are shown in duplicates,
for time point 0 the first two replicates were utilized. RNA
was isolated as described above (RNeasy, Qiagen) and gene
expression was analyzed on GeneChip R© Mouse Genome 430
2.0 Arrays (Affymetrix). The microarray data is accessible
via the following URL: https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE69939.
Microarray Analysis
Principal component analysis was performed on the global
transcriptional profiles. The first two principal components
explained most of the variance in the data set (PC1: 58.4%, PC2:
9.7%, 68.1% in total).
To analyze significant gene regulation, we applied a linear
regression model with the Limma package (Ritchie et al., 2015).
Gene expression values yi were modeled to be explained by
time frames t (early, intermediate and late) and condition c
(IL-6 and control). The significance threshold of Benjamini–
Hochberg adjusted p < 0.01 was implemented. For example
“early IL-6 response” was extracted from the global linear model
by performing contrast analysis of early IL-6 vs. respective
(unpaired) early control samples.
All analyses were performed in R Statistical software (www.r-
project.org).
Ontology analysis of the three response lists was performed
using amodel-based ontology analysis (http://nar.oxfordjournals.
org/content/early/2010/02/19/nar.gkq045.full) using Wiki
Pathways and implementing an enrichment threshold using
pathways with a probability of being regulated> 0.5.
Mass Spectrometric Analysis
Primary mouse hepatocytes (5 × 106 cells per 10 cm dish)
were cultivated for 40 h in serum-depleted medium. Cells were
then serum- and dexamethasone-depleted for 5 h in starvation
medium, stimulated with 40 ng/mL hIL-6 for 18min, and
lysed in Nonidet P-40 lysis buffer. STAT3 immunoprecipitations
were subjected to 10% SDS-PAGE and proteins were stained
with SimplyBlue SafeStain (Life Technologies). STAT3-α bands
were excised, cut into small pieces (∼1 mm3) and destained
with 0.07M NH4HCO3 buffer/30% acetonitrile. Gel pieces
were dehydrated in 0.1% trifluoroacetic acid/50% acetonitrile,
followed by protein in-gel reduction with 10mM dithiothreitol
(45min at 56◦C) and alkylation with 55mM iodoacetamide for
30min in the dark. Digestions were performed with AspN +
LysC in 0.05M NH4HCO3 buffer at 37
◦C overnight. Following
incubation, internal peptide-/phospho-peptide one-source ratio
standards for quantification of STAT3 Tyr-705 phosphorylation
were added. The standard consists of the isotope labeled
[13C5,
15N] peptides DPGSAAP-pY-[L+6Da]-K and DPGSAAP-
Y-[L+6Da]-K at an exact molar ratio of 1:1. Following standard
addition to the gel pieces and 15min of shaking the supernatant
of each sample was collected. Peptide extraction was finished
by sequentially adding appropriate volumes of eluents to the gel
pieces, shaking them and combining all the supernatants for each
sample. The eluents were (i) acetonitrile, (ii) 5% formic acid, and
(iii) acetonitrile. The collected sample volumes were reduced by
speedvac and purified by applying the ZipTip method (Millipore)
according to the manufacturer’s recommendations. Final sample
volumes of 5 µl were injected into an ultra-performance liquid
chromatography (nanoUPLC, nanoAcquity, Waters) online
coupled to a Q Exactive Plus-Orbitrap mass spectrometer
(Thermo). For details about preparation and application of
peptide-/phosphopeptide one-source ratio standards see Hahn
et al. (2011) and Boehm et al. (2014).
Generation of mKate2-STAT3 Knock-In
Mouse
To generate the mKate2-STAT3 reporter gene, we based the
fusion construct on earlier studies (see Herrmann et al., 2007;
Samsonov et al., 2013) and inserted the mKate2-coding sequence
in front of the first exon of STAT3 by BAC recombineering.
An insert harboring mKate2 and part of STAT3 as well as
the Neomycin selection cassette flanked by homologous arms
was retrieved into PL253 vector (NCI Frederick; Liu et al.,
2003) to obtain the gene targeting construct. Gene targeting
was performed in the mouse embryonic stem (ES) cell line
JM8A3 (Pettitt et al., 2009) by electroporation of the linearized
gene targeting construct followed by selection with G418 (Life
Technologies) and Ganciclovir. Correctly targeted ES cell clones
were identified by long-range PCR and confirmed with southern
blot. Chimera were generated by blastocyst injection of correctly
targeted ES clones. Male chimera were bred with female
wild type C57BL/6N mice to promote germline transmission
of the reporter gene. Germline transmission was identified
by genotyping PCR. The selection cassette was removed by
subsequently crossing heterozygous mice with Cre expressing
mice (Schwenk et al., 1995). Only heterozygous mice were
used for the experiments, because it was so far not possible to
obtain homozygous mKate2-STAT3 reporter mouse offsprings.
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See Appendix for more information about gene targeting and
genotyping.
Live-Cell Imaging
Primary hepatocytes (15,000 cells per well, 96-well plate
format) derived from mKate2-STAT3 heterozygous knock-in
mice (Appendix Supplementary Experimental Procedures and
Table S1) were infected with adeno-associated viruses encoding
mCerulean-labeled histone-2B during adhesion. Cells were
cultivated as described above, stimulated with inhibitor/ligand,
and imaged using a Nikon Eclipse Ti Fluorescence microscope
in combination with NIS-Elements software. Temperature
(37◦C), CO2 (5%), and humidity were held constant through
an incubation chamber enclosing the microscope. Three
channels were acquired for each position: bright-field channel,
STAT3 channel (mKate2), and nuclear channel (CFP). Image
analysis was performed using Fiji software (Schindelin et al.,
2012), and data were processed using R software (The R
Foundation). The ratio of nuclear to cytoplasmic (nuc/cyt)
mKate2-STAT3 was determined in 20 cells, facilitated by
manual segmentation of nuclei (histone-2B-mCerulean
signal) and whole cells (bright-field channel). The mean
concentration of cytoplasmic STAT3 was derived assuming
constant overall mKate2-STAT3. mKate2 background was
determined in wild-type nuclei and cytoplasm and subtracted
accordingly.
Mathematical Modeling
A mathematical multi-compartment model describing IL-
6 signaling in primary mouse hepatocytes was developed.
The model is described by a set of coupled non-linear
differential equations implemented using the Data2Dynamics
software package (Raue et al., 2015) In each simulated
experiment, the model is equilibrated to steady state prior to
treatment with inhibitors or stimulation. Considering the size
and complexity of the model and experimental data, model
calibration was performed in two separate stages. The core model
describes receptor production, degradation and phosphorylation
as well as activation and translocation of STAT3, negative
feedback by SOCS3 and the effect of inhibitors, while the
downstream model describes the transcription of the various
APP genes. Parameters for the upstream and downstream
model were estimated separately. All model parameters were
estimated directly from the experimental data using Maximum
Likelihood Estimation. Several experiments required the use of
scaling, offset and error model parameters that were estimated
simultaneously with the dynamic parameters. For the core
model, 270 parameters (of which 22 dynamic parameters) were
estimated on a total of 2220 data points. For the downstream
components, we estimated 471 additional parameters (of
which 29 dynamic parameters) on a total of 2,288 data
points.
To evaluate that parameters are identifiable (Maiwald
et al., 2016), profile likelihood calculation followed by
either model reduction or additional data acquisition were
iteratively applied. For a full mathematical description
of the model, including a detailed description of the
iterative model building and reduction steps see Appendix
section 3.5.
Local Parameter Sensitivity Analysis (LPSA) was performed
with respect to model parameters. The local parameter sensitivity










Here y refers to the model output at the perturbed parameter,
while yref indicates the reference output. As model output, we
selected the integral of the mRNA levels. Analogously, p and pref
refer to the parameter value in the perturbed and reference state.
These sensitivities are then computed for each of the APP genes
and averaged. To assess how much uncertainty there is in these
sensitivities, we computed an LPSA for each parameter set in our
parameter profile likelihoods and reported the maximum and
minimum value encountered within the confidence intervals of
all parameters.
The mathematical model is available to the community at the
biomodels database as well as on www.data2dynamics.org.
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